Advertisement
U.S. markets open in 3 hours 21 minutes
  • S&P Futures

    5,303.75
    -4.50 (-0.08%)
     
  • Dow Futures

    40,135.00
    -9.00 (-0.02%)
     
  • Nasdaq Futures

    18,478.75
    -25.00 (-0.14%)
     
  • Russell 2000 Futures

    2,135.20
    -3.20 (-0.15%)
     
  • Crude Oil

    81.94
    +0.59 (+0.73%)
     
  • Gold

    2,218.40
    +5.70 (+0.26%)
     
  • Silver

    24.57
    -0.19 (-0.76%)
     
  • EUR/USD

    1.0782
    -0.0048 (-0.44%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    13.00
    +0.22 (+1.72%)
     
  • GBP/USD

    1.2603
    -0.0035 (-0.28%)
     
  • USD/JPY

    151.4530
    +0.2070 (+0.14%)
     
  • Bitcoin USD

    70,635.08
    +701.24 (+1.00%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,971.36
    +39.38 (+0.50%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

BIO-key International, Inc. (NASDAQ:BKYI) Q4 2022 Earnings Call Transcript

BIO-key International, Inc. (NASDAQ:BKYI) Q4 2022 Earnings Call Transcript March 31, 2023

Operator: Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the BIO-key International Fourth Quarter Conference Call. During management's prepared remarks, all participants will be in a listen-only mode. Afterwards, listeners will be invited to participate in a question-and-answer session. As a reminder, this conference is being recorded today, Friday, March 31, 2023. Now I would like to turn the call over to Bill Jones, Investor Relations. Please proceed.

William Jones : Thank you, thank you for joining todays call. Participating today are BIO-key's Chairman and CEO, Mike DePasquale; CFO, Cecilia Welch. VP of Channels for North America, Galen Rodgers, and myself. I will remind everyone that today's conference call and webcast as well as answers to questions may include forward-looking statements, which are subject to certain risks and uncertainties that may cause actual results to differ from those projected. Words such as anticipate, believe, estimate, expect and plan and similar words typically identify and express forward-looking statements. These forward-looking statements are made based on management's beliefs and assumptions today, using information currently available pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.

For a complete description of these and other risk factors that may affect the future performance of BIO-key, please see risk factors in the company's annual report filed on Form 10-K with the Securities and Exchange Commission. Listeners are cautioned not to place undue reliance on such forward-looking statements, which speak only as of today's date. BIO-key company undertakes no obligation to revise or disclose revisions to such forward-looking statements to reflect future events or circumstances occurring after today. And with that, I will turn the call over to Mike. Mike?

Michael DePasquale: Thanks, Bill. Good morning, and thank you for joining our call today. After my remarks, I want to let one of our new Senior Sales Executive, Galen Rodgers introduce himself, and review sales and channel initiatives for 2023. Ceci will provide financial highlights, and then we'll open the call to investor questions. From a high level, we had a strong close to the year, achieving full year revenue of $7 million, which met the low end of our revenue guidance. More importantly, we made tremendous progress in 2022, solidifying our global reach and brand, while continuing to expand our base of high margin annual recurring revenue. We now serve 10s of millions of end users across 600 customers globally, leveraging our PortalGuard platform in North America and Swivel Secure in Europe and the Middle East.

We've evolved our business to a software-as-a service or a SaaS based model, or more precisely what we refer to as ID as-a service or IDaaS. Our 2022 net loss increased due to added expenses from the acquisition of Swivel Secure, our PortalGuard, IDaaS sales and marketing built, and the active development of enhanced features for our solutions, including MobileAuth. Additionally, our personnel and other costs reflected general inflation based increases that were experienced by most companies in 2022. In response, we have been taking steps to reduce costs wherever possible, including streamlining our headcount and overhead. We're also looking to enhance our financial liquidity by working to reduce hardware inventories, which we were increased to navigate potential supply chain challenges back in late 2021 and early 2022.

We had $4.8 million of inventory at year end, and we have a goal to reduce that by at least half in the first two quarters of 2023. Importantly, during 2022, BIO-key achieved higher software revenues in North America, Europe, the Middle East, South America and Asia, give an ongoing funding and rollout delays for government sponsored civil ID programs in Africa, it was the one region that did not achieve growth. However, we are cautiously optimistic that things could begin to turn around and Africa, in particular Nigeria, as we progress through 2023. Innovation remains critical to BIO-key's growth and competitive position. And during 2022 we made significant progress expanding and enhancing our solutions, including our password lists and mobile solutions, which include our proprietary identity bound biometrics, or IBD capabilities.

We launched enhancements to our Mobile Authenticator app in Q3 2022. And we also developed and launched and updated Admin panel, that delivers an improved user experience for PortalGuard users. These successful launches received excellent feedback from customers and prospects. Our PortalGuard IDaaS franchise continued to build momentum in 2022. Further expanding penetration of customers across higher education, county governments and business enterprises. Customers prefer a PortalGuard for its effective security, ease of use, scalability and attractive value proposition. In 2023, we will look to increase PortalGuards penetration of these verticals, while also pursuing opportunities in new adjacent markets. To enhance the global reach of our solutions and sales, we have expanded our direct sales team, which is supported by both traditional and digital marketing campaigns.

In conjunction with the management transition announced in January 2023, we recruited Galen Rodgers as VP of Channels, and Chad Carter, as VP of Sales, both in North America. I will turn the call over to Galen in a moment. But let me first say that we are very excited to bring their experience, skill sets and leadership to our company, as they each have decades of valuable sales experience within larger organizations in our industry in space. It cannot go unnoticed that cybersecurity challenges continue to grow in both the number of episodes and their severity. To counter this trend, industry forecasters expect another record level of cybersecurity spending in 2023. And we believe BIO-key is well positioned to benefit. To date, nearly a third of all organizations have launched passwordless authentication solutions, which is up from 22% last year, but still leaves a very substantial sales opportunity on the table.

We think our multi factor solutions with identity bound biometrics offer a unique and cost effective solution for organizations across most verticals, and use cases, especially for those looking to implement passwordless or zero trust solutions, which are critical in today's environment. I could go on, but let me just say that we believe our substantial direct sales and partner distribution footprint positions us well around the globe. We are working a solid pipeline of customer opportunities, including several that are very substantial and scale. While we also continue to build this pipeline through our sales and marketing outreach. The true force multiplier for us is our Channel Alliance Program or CAP. That is being spearheaded in EMEA by our Managing Director Alex Rocha, and here in North America by Galen.

As a result, we feel confident for a continued growth in 2023 and beyond. We disclose today that we expect Q1 2023 revenue will be at a record level, getting us off to a strong start to the year. And rather than attempt to project a specific revenue range for 2023, we've instead indicated that we expect 2023 will be a period of substantial top line and bottom line improvement. This outlook is supported by our strong start in Q1, along with our growing base of high margin contracted annual recurring revenues, which we currently estimate to be at approximately $7 million in run rate. Based on these factors, we feel very confident, that substantially exceeding our 2022 top and bottom line performance, reducing our cash burn and moving towards breakeven and profitability.

Before I turn the call over, I'll note that a recent report by Houlihan and Lokey showed median valuation multiples for public companies in the cybersecurity software industry, range from a low of three to seven or eight times revenue on an enterprise basis, depending upon expected growth. Obviously BIO-key is trading at much less than that based on 2022 results. And we are off to a strong start in 2023 which can meet solid appreciation for all of our stakeholders. I'll now turn the call over to Galen Rodgers, who joined us in early 2023, to briefly review how he is working to take BIO-key sales reach to higher levels in 2023. Galen?

Galen Rodgers: Thank you very much, Mike. First about myself. I have 23 years in this business with 16 years in technology sales, with the majority of my time has been in Channel Sales. Most recently, I was Director of Strategic Channel at Ping Identity. From a channel perspective, our mission is building scalable, dependable, and collaborative avenues that contribute to revenue growth and value, while expanding our market presence globally. More specifically, what this means is that we have focused on the core objectives of reaching new markets, building pipeline, generating partnerships, and increasing our deal size, and then tacking specific higher value opportunities. Higher value opportunities in cybersecurity would include such things as, established cybersecurity systems integrators, large account resellers, and technology partnerships.

From there we manage and analyze what's working and not working, so that we can continue to enhance our process and performance. We currently have a great base of partners in our Channel Alliance Partner Program, with over 500 partners globally. We have key distribution partners such as Intellisis, 3i, and DLT, a TD SYNNEX company and our sled partner. We have key value added reseller relationships that we have certain important tech alliances with firms like AWS, Beyond Trust and ForgeRock. We also have key cyber managed security service provider relationships, and one of my initiatives in 2023, is to roll out our new enhanced partner program to new and curtain current partners. This will provide structure and incentives to evangelize, sell licenses, and provide services to the market.

This program will reward cybersecurity partners differently from the previous program by training partners to implement our solution and in turn provide additional sourced opportunities, which I believe is low hanging fruit to drive the business. From a numbers perspective, our plan includes 1 million of channel sourced bookings in 2023, and in addition of 3.5 million in future opportunities to the sales pipeline, from channel source to deals. We have a number of new partners we are targeting. And obviously I won't discuss those for competitive reasons. However, we have a comprehensive list of prime targets. I'm very excited for the opportunity to be part of the BIO-key team, and I'm looking forward to taking our channel development and productivity to the next level.

With that brief overview, I'll provide an update from the VP of Sales. Chad Carter, who has joined the BIO-key team. Chad has been in the industry for 25 years, specifically in network and security sales. He recently finished a six years with European cybersecurity software provider, Wallex, building their UST. That team was up to eight people and primarily self-sufficient. He made the move to BIO-key, because he really liked their products, biometric differentiation, and market opportunity, and he was ready for a new challenge. Our team is focused on some core goals for 2023, which include increasing average deal size, better prospecting, a targeted selling of enterprises with bigger budgets, and most importantly, channel enablement. We believe that the channel needs to be involved in almost every deal involved early.

25 Highest Paying Jobs in the US
25 Highest Paying Jobs in the US

Photo by Campaign Creators on Unsplash

This is how channel and field sales work together. We will assign a partner as often as possible when it makes sense. Because to gain their mind share and focus, you need to be feeding the deals into the channel and get deals in return. It's really a symbiotic relationship when it works best. When talking about increasing deal size. It really involves several factors that start even before you engage with the customer. We are focusing on longer term opportunities like three year deals that are paid upfront. This is achieved through better prospecting, targeting companies by revenue, targeting larger prospects, targeting prospects near current customers, focusing on key verticals outside of what we internally call sled, which is state and local counties, municipalities and education, which has been PortalGuards sweet spot.

Chad's theory with bigger prospects has always been land and expand, meaning let's get our foot in the door and we can grow the relationship over time. In this regard, we have been focusing on $500 million to $5 billion companies. meaning account based marketing, taking a narrower focus and going deeper -- by thinking bigger, we can increase our average selling price quite substantially as much as 50% in the first year. All these things can lead to larger deal size. In line with our partner strategy, we're doing account mapping to align with our channel partner sales teams to drive new opportunities. And we're implementing a more formal referral selling program, as we found that customers are often open to giving a referral versus being a case study.

Again, some of this is basic, but as previously mentioned, we see some low hanging fruit strategies and tactics need to be communicated and executed and we're in that process. This is what the team is looking on in North America. And with that, I will turn the time over to our CFO, Ceci Welch.

Cecilia Welch: Thank you, Galen. Please let me review some of our financial highlights. Q4 €˜22 revenue rose 88% to $1.8 million from $9.9 million in Q4 €˜21, reflecting higher software license and service fees, including the benefit of the Swivel Secure acquisition in March of 2022. Likewise, 2022 revenue rose 37% to $7 million versus $5.1 million in 2021. Both current year periods, higher software license and service fees were partially offset by lower hardware revenue. Revenue from software licenses increased 92% in Q4 €˜22, and 79% to $4.6 million in fiscal year 2022, reflecting the addition of Swivel Secure and new quarterback customers and existing recurring revenue contracts. Service revenue increased 104% in Q4 €˜22, and increased 41% to $1.8 million for the full year 2022.

With the majority representing recurring maintenance and software and support. Recurring service revenue increased 13% to $1.2 million in 2022, due largely to increase maintenance related to software licenses. Non-recurring customer services increased 216% to $546,000 in 2022, due to increase new customer installations, Swivel service fees and the conversion to cloud platform. As our customer base continues to grow, we expect service revenues to continue to increase. Our sales increased 25% in Q4 €˜22, but decreased 50% to $646,000 for the year. The annual decline was due to the sales to an international government agency in Nigeria in 2021 that did not recur in 2022, due to delayed rollout of the government project. Strength in Q4 €˜22 was attributable to new customer orders in addition to expanding existing installations.

Gross profit increased to $1.2 million in Q4 €˜22, versus $0.6 million in Q4 €˜21. Due to higher revenue for a better realized gross margin of 67% versus 60% in the prior year period. For the full year, gross profit margins improved to 71% in 2022, from 67% in fiscal 2021. Total operating expenses increased to $5.9 million in Q4 '22, from $2.6 million in Q4 €˜21. The full year 2022 operating expenses increased to $14.7 million from $8.4 million. The 2022 periods reflect the addition of the Swivel Secure operations, non-cash impairment charges to goodwill, and $1.8 million of the higher SG&A and research and development and engineering expenses. Higher SG&A costs includes marketing expenses, legal and professional fees and other expenses incurred in connection with the acquisition of Swivel and our ADB capital loan, bad debts, an allowance for doubtful accounts.

Moving forward in 2023, we do not expect bad debt and allowance for doubtful accounts to recur. Higher R&D expense reflected increase in personnel costs and product development activity, including the Q3 launch of significant enhancements and updates in our MobileAuth app. We expect lower R&D expenses in 2023, as outside resources for 2022 product development activities are no longer required. As such BIO-key recorded a Q4 €˜22 operating loss of $4.8 million versus an operating loss of $2 million in Q4 €˜21. With the increase primarily -- due primarily to the Q4 2022 non-cash goodwill exam and charge. BIO-key's 2022 operating loss increased to $9.7 million from $4.9 million in '21, due to higher costs and the goodwill impairment. Likewise, BIO-key reported a net loss of $5.1 million to $0.62 per share in Q4 €˜22, versus a net loss of $2 million or $0.26 in Q4 €˜21.

The company reported 2022 net loss of $10.2 million, or $1.26 per share versus a net loss of $5.1 million or $0.65 per share in 2021. BIO-key ended the year with current assets of $9.7 million, including $2.6 million of cash and cash equivalents, $1.6 million accounts receivable and $4.8 million of inventory. BIO-key had a current note payable, the current portion of the loan due is $2.2 million. That concludes my remarks. Now I'm going to turn the call back over to the operator for Q&A.

See also 15 Best Retirement Communities For Active Adults and 25 Countries with the Best Hospitals in the World.

To continue reading the Q&A session, please click here.

Advertisement